Gefitinib-induced pneumonitis in non-small cell lung cancer: radiological and clinical findings in five patients

Clinical Imaging

Volumn 31, Issue 5, 2007, Pages 306-312

  Park, Hee Sun ^a   Lee, Hyun Ju ^a   Im, Jung Gi ^a   Goo, Jin Mo ^a   Lee, Chang Hyun ^a   Park, Chang Min ^a   Chun, Eun Ju ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Gefitinib; Iressa; Lung; pneumonitis, CT, simple radiograph

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DISEASES; GLASS; OPACITY; PATIENT TREATMENT; RADIOLOGY;

GEFITINIB; IRESSA; PNEUMONITIS; SIMPLE RADIOGRAPHS;

TUMORS;

CARBOPLATIN; CISPLATIN; COTRIMOXAZOLE; DOCETAXEL; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MALE; PNEUMONIA; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PNEUMONIA; QUINAZOLINES;

EID: 34548314473     PISSN: 08997071     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinimag.2007.04.023     Document Type: Article

References (23)

1. Herbst R.S., and Kies M.S. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist 7 Suppl 4 (2002) 9-15
2. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
3. Ranson M. ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist 7 Suppl 4 (2002) 16-24
4. Penne K., Bohlin C., Schneider S., et al. Gefitinib (Iressa, ZD 1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs 28 (2005) 481-486
5. Caponigro F., Basile M., de Rosa V., et al. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. Anticancer Drugs 16 (2005) 211-221
6. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20 (2002) 2240-2250
7. Herbst R.S., Maddox A.M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20 (2002) 3815-3825
8. Okamoto I., Fujii K., Matsumoto M., et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 40 (2003) 339-342
9. Inoue A., Saijo Y., Maemondo M., et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361 (2003) 137-139
10. Ohyanagi F., Ando Y., Nagashima F., et al. Acute gefitinib-induced pneumonitis. Int J Clin Oncol 9 (2004) 406-409
11. Miya T., Ono Y., Tanaka H., et al. Radiation recall pneumonitis induced by gefitinib (Iressa): a case report. Nihon Kokyuki Gakkai Zasshi 41 (2003) 565-568
12. Rabinowits G., Herchenhorn D., Rabinowits M., et al. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs 14 (2003) 665-668
13. Inomata S., Takahashi H., Nagata M., et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 15 (2004) 461-467
14. Kitajima H., Takahashi H., Harada K., et al. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respirology 11 (2006) 217-220
15. Seto T., Seki N., Uematsu K., et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology 11 (2006) 113-116
16. Janmaat M.L., and Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 8 (2003) 576-586
17. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 Suppl 4 (2002) 2-8
18. Endo M., Johkoh T., Kimura K., et al. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology group. Lung Cancer 52 (2006) 135-140
19. Madtes D.K., Rubenfeld G., Klima L.D., et al. Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 158 (1998) 424-430
20. Madtes D.K., Busby H.K., Strandjord T.P., et al. Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats. Am J Respir Cell Mol Biol 11 (1994) 540-551
21. Hardie W.D., Prows D.R., Piljan-Gentle A., et al. Dose-related protection from nickel-induced lung injury in transgenic mice expressing human transforming growth factor-alpha. Am J Respir Cell Mol Biol 26 (2002) 430-437
22. Hardie W.D., Prows D.R., Leikauf G.D., et al. Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-alpha. Am J Physiol 277 (1999) L1045-L1050
23. Camus P., Kudoh S., and Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 91 Suppl 2 (2004) S18-S23